[go: up one dir, main page]

MX2017012387A - Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer. - Google Patents

Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer.

Info

Publication number
MX2017012387A
MX2017012387A MX2017012387A MX2017012387A MX2017012387A MX 2017012387 A MX2017012387 A MX 2017012387A MX 2017012387 A MX2017012387 A MX 2017012387A MX 2017012387 A MX2017012387 A MX 2017012387A MX 2017012387 A MX2017012387 A MX 2017012387A
Authority
MX
Mexico
Prior art keywords
useful
treatment
present description
cyclo
cancer
Prior art date
Application number
MX2017012387A
Other languages
English (en)
Other versions
MX376112B (es
Inventor
Sridharan Rajagopal
Vadivelu Saravanan
Chinnapattu Murugan
Kumar Gondrala Pavan
Sivanandhan Dhanalakshmi
Mulakala Chandrika
Original Assignee
Jubilant Biosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Biosys Ltd filed Critical Jubilant Biosys Ltd
Publication of MX2017012387A publication Critical patent/MX2017012387A/es
Publication of MX376112B publication Critical patent/MX376112B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción describió compuestos heterocíclicos de la Fórmula I o, sus estereoisómeros, sales farmacéuticamente aceptables, complejos, hidratos, solvatos, tautómeros, polimorfos, mezclas racémicas, formas ópticamente activas y derivado farmacéuticamente activo de los mismos y composiciones farmacéuticas que los contienen como el ingrediente activo; la presente descripción también describe la síntesis y caracterización de compuestos mencionados anteriormente para exhibir alta actividad anticancerígena; los compuestos de la presente descripción son útiles como medicamentos y su uso en la elaboración de medicamentos para tratamiento, prevención o supresión de enfermedades, y condiciones mediadas por una o más familias BET de bromodominios. (ver Fórmula).
MX2017012387A 2015-03-30 2016-03-30 Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer. MX376112B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1636CH2015 2015-03-30
PCT/IN2016/050098 WO2016157221A1 (en) 2015-03-30 2016-03-30 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017012387A true MX2017012387A (es) 2018-06-11
MX376112B MX376112B (es) 2025-03-07

Family

ID=56015058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012387A MX376112B (es) 2015-03-30 2016-03-30 Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer.

Country Status (16)

Country Link
US (2) US10689390B2 (es)
EP (1) EP3277683B1 (es)
JP (1) JP6764877B2 (es)
KR (1) KR102588109B1 (es)
CN (1) CN107548393B (es)
AU (1) AU2016242473B2 (es)
BR (1) BR112017020739B1 (es)
CA (1) CA2980266C (es)
DK (1) DK3277683T3 (es)
ES (1) ES2911886T3 (es)
IL (1) IL254528B (es)
MX (1) MX376112B (es)
PL (1) PL3277683T3 (es)
PT (1) PT3277683T (es)
RU (1) RU2721120C2 (es)
WO (1) WO2016157221A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210581T1 (hr) * 2015-09-09 2021-05-28 Jubilant Biosys Limited Triciklički kondenzirani derivati piridin-2-ona i njihova upotreba kao inhibitora brd4
KR20190075131A (ko) * 2016-11-10 2019-06-28 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드 질소 함유 거대 고리계 화합물, 이의 제조 방법, 약물 조성물 및 용도
WO2019214399A1 (zh) * 2018-05-10 2019-11-14 罗欣药业(上海)有限公司 苯并七元杂环类化合物、其制备方法、药物组合物及应用
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
JPWO2008133288A1 (ja) 2007-04-25 2010-07-29 第一三共株式会社 三環性アリール化合物
EP2276767B1 (en) * 2008-03-31 2014-05-07 Genentech, Inc. Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
ES2526671T3 (es) * 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
MA38346B1 (fr) * 2013-02-19 2019-05-31 Bayer Pharma AG 2,3-benzodiazépines bicyclo- et spirocyclosubstituées
EP2970330B1 (en) * 2013-03-12 2019-04-17 AbbVie Inc. Tetracyclic bromodomain inhibitors
WO2015018520A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
US9814728B2 (en) 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)

Also Published As

Publication number Publication date
US20200331926A1 (en) 2020-10-22
KR102588109B1 (ko) 2023-10-12
RU2017135205A3 (es) 2019-07-17
US10689390B2 (en) 2020-06-23
DK3277683T3 (en) 2022-05-02
RU2017135205A (ru) 2019-04-10
KR20170132278A (ko) 2017-12-01
PT3277683T (pt) 2022-06-28
WO2016157221A1 (en) 2016-10-06
BR112017020739A2 (pt) 2018-07-17
CN107548393A (zh) 2018-01-05
AU2016242473B2 (en) 2020-06-25
US20180282345A1 (en) 2018-10-04
RU2721120C2 (ru) 2020-05-15
CA2980266A1 (en) 2016-10-06
CN107548393B (zh) 2021-03-02
EP3277683A1 (en) 2018-02-07
JP6764877B2 (ja) 2020-10-07
IL254528A0 (en) 2017-11-30
HK1248686A1 (zh) 2018-10-19
CA2980266C (en) 2025-05-06
ES2911886T3 (es) 2022-05-23
IL254528B (en) 2020-11-30
MX376112B (es) 2025-03-07
JP2018510203A (ja) 2018-04-12
AU2016242473A1 (en) 2017-10-26
EP3277683B1 (en) 2022-03-09
BR112017020739B1 (pt) 2023-03-14
NZ735972A (en) 2024-08-30
US11319326B2 (en) 2022-05-03
PL3277683T3 (pl) 2022-05-23

Similar Documents

Publication Publication Date Title
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
MX2018002738A (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CO2018001268A2 (es) Derivados de heteroarilo como inhibidores de parp
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
UY40230A (es) Macrociclos con grupos P2’ heterocíclicos como inhibidores del factor XIa y composiciones farmacéuticas que los comprenden
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
BR112016016844A2 (pt) Compostos heterocíclicos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
MX2018003993A (es) Inhibidores de isoindolinona de la interaccion mdm2-p53 que tienen actividad antineoplasica.
CO2017009353A2 (es) Derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
CO7280475A2 (es) Derivados de azaindol que actuan como inhibidores de pi3k
MX2017012387A (es) Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer.
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
UY36124A (es) Derivados de carboxamida
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
AR099867A1 (es) Compuestos imidazobenzotiazolo fusionados
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones

Legal Events

Date Code Title Description
FG Grant or registration